Advocacy Group Wants TAVR Changes, Urging Trump Admin to ‘Stop Getting in Between Patients and Their Doctors’

Why It Matters

Expanding TAVR access could lower procedural costs, speed treatment for aortic stenosis, and reshape Medicare’s heart‑care spending.

Key Takeaways

• 77% of poll respondents support Medicare covering TAVR like surgery
• CMS may drop CED rules, easing data‑collection burdens
• Asymptomatic patients could qualify for TAVR under new policy
• Optional surgical consults may streamline multidisciplinary heart‑team meetings

Pulse Analysis

Transcatheter aortic valve replacement has rapidly become the preferred therapy for aortic stenosis, especially among older patients who face higher surgical risk. By delivering a valve via a catheter, TAVR avoids the trauma of open‑heart surgery, shortens hospital stays, and has demonstrated comparable mortality outcomes in recent trials. Health‑economics analyses estimate roughly $10,000 in first‑year savings per patient, driven by reduced intensive‑care utilization and faster return to daily activities. These cost efficiencies make TAVR an attractive candidate for broader Medicare coverage, particularly as the U.S. population ages and the prevalence of valve disease rises.

CMS’s current coverage framework relies on evidence‑development (CED) requirements, mandating that providers enroll patients in registries or trials to continue reimbursement. Critics argue that CED creates administrative friction and delays care for patients who could benefit immediately. The agency’s proposed reforms—eliminating CED, extending eligibility to asymptomatic individuals, and allowing surgical consultation to become optional—signal a shift toward value‑based, patient‑centered reimbursement. If adopted, these changes could accelerate adoption rates, reduce procedural backlogs, and generate measurable savings for the Medicare trust fund, while also prompting manufacturers to focus on next‑generation devices that further lower costs and improve durability.

The advocacy push is bolstered by public sentiment; a recent poll commissioned by the Alliance for Aging Research found strong bipartisan support for expanding TAVR access. Professional societies such as the ACC, AATS, and SCAI have voiced cautious optimism, emphasizing the need to balance access with rigorous outcome monitoring. As the June decision approaches, stakeholders—from device makers to cardiology groups—are positioning themselves to influence policy outcomes. A favorable ruling would not only reshape clinical pathways but also create a precedent for how Medicare evaluates emerging minimally invasive technologies, potentially accelerating the adoption of other high‑impact innovations across the health‑care system.